MICROBIOTIX
MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
ABOUT US
Phage, Microbiome
& Beyond
MICROBIOTIX
MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
ABOUT US
Phage, Microbiome
& Beyond
Phage,
Microbiome
& Beyond
We develop bacteriophage and microbiome based treatments against superbugs
At MicrobiotiX, our goal is to develop bacteriophage-based treatments for multidrug-resistant bacteria, microbiome-based treatments using microbiota banking, and treatments related to autoimmune diseases and other untreatable diseases in the future. MicrobiotiX is a biotech company specializing in microbiome research established by professors from Yonsei Medical Center. With our microbiota collection and bacteriophage library we develop various treatments for multidrug-resistant bacteria and incurable diseases through exploring the interconnected relationship between the phages present in your intestines and the microbiome. We have built the world’s leading bacteriophage library over 15 years along with state-of-the-art research techniques in the field of bacteriophage and microbiome. In addition, we have built a GMP facility for a global scale up.
AT A GLANCE
Phage library of Gram-negative MDR pathogens
Possession of Asia’s 2nd oldest microbiota bank
Received approval for free pre-clinical serivce by the US institution
Pre-Series B investment round (DSC, Schmidt, SUP, Shinhan Capital)
A venture established by specialists from Yonsei Medical Center
Got selected to be part of Shinhan2Bridge program
Joint research with CJ Bioscience
Establishment of a cGMP-class facility (CDMO service)
MICROBIOTIX - CEO
Antimicrobial resistance is one of the 6 major challenges facing humanity
Antimicrobial agents are drugs that have saved countless lives since their discovery, but their development and pharmaceutical process is very slow and arduous. Microorganisms are gaining resistance to these antimicrobial agents. This undermines all of the hard work put into their development. This is due to the extreme diversity and genetic flexibility of these microorganisms. This problem is only expected to worsen in the future for 2 reasons: antimicrobial candidates are dwindling, and even with large investments, the new antimicrobial mechanism will be countered with just a few generations of mutations. Therefore, there is an urgent need to supplement or replace the existing antibacterial treatment framework. The countermeasures we must take are clear. Recently, the NIH in the United States proposed a shift to explore alternative therapies to overcome antimicrobial resistance, including bacteriophage therapy and synthetic microbiota. Yonsei University’s diagnostic laboratory, the academic foundation of MicrobiotiX, and the Institute of Bacterial Resistance have conducted a world-class antimicrobial resistance study. During this research, many world-first discoveries were made. The research team then explored innovative ways to overcome antimicrobial resistance and from this discussion MicrobiotiX was founded. The specific method that MicrobiotiX is currently pursuing is through bacteriophage therapy. Through bacteriophages, we want to reset the relationship between humans and antimicrobial resistant bacteria. Through, both Korean and American research teams, we are investigating phages to be used in preclinical and clinical trials. I’ll continue to work hard to push our research forward and I look forward to your support.
Dongeun Yong, CEO
MICROBIOTIX
KEY RESEARCHERS
Yong, Dongeun Yonsei University’s School of Medicine Department of Laboratory Medicine Director of Infectious Diseases |
Cheon, Jaehee Yonsei University’s School of Medicine Department of Gastroenterology Professor |
Park, Mooseok Yonsei University’s School of Medicine Department of Pulmonology Professor |
Lee, Sangkil Yonsei University’s School of Medicine Department of Gastroenterology Chief of Gastric Cancer Center |
Choi, Junyong Yonsei University’s School of Medicine Department of Infectious Diseases Professor |
MICROBIOTIX
A BRIEF HISTORY
2022 | Received approval from US institution for free pre-clinical services Pre-series B with DSC Investment VC and Schmidt Bridge investment partners |
2021 | Pneumonia (Sepsis) treatment against pseudomonas aeruginosa infection. MP001 (first pipeline) got accepted to pre-clinical project (3.5 Billion) CJ Bioscience Co-development involving P. aeruginosa-caused pneumonia and pulmonary hematosis (MOU) SUP, Shinhan Capital Pre-A investment round DSC Investment VC, Schmidt A investment round Initiation of virome based treatment through FMT & FFT |
2020 | Transfer of 300 types of bacteriophages from Yonsei Medical Center |
2019 | IRB approval for bacteriophage therapy in clinical trials |
2018 | Ten bacteriophage-related patents transferred from Yonsei Medical Center |
2017 | Establishment of microbiota bank and FMT delivery for clinical use in hospitals |
2016 | MicrobiotiX founded |
PARTNERS
A Network
of Hospitals Nationwide
Seoul Yonsei Medical Center, Severance Hospital |
Gangwon province Hallim University |
Gwangju Metropolitan Area Jeollam University Hospital |
Gyeonggi Province Catholic University , St. Mary’s Hospital (Bucheon) |
Daejeon Metropolitan Area Daejeon Eulji University Hospital |
Daegu Metropolitan Area Daegu Fatima Hospital |
Busan Metropolitan Area Goshin University, Gospel Hospital |
Incheon Metropolitan Area Gacheon University, Gil Hospital |
Jeollabuk Province Jeonbuk University Hospital |
Ulsan Metropolitan Area Ulsan University Hospital |
Jeju Province Jeju University Hospital |
CONTACT
Phage, Microbiome & Beyond
We develop bacteriophage and microbiome based treatments against superbugs
At MicrobiotiX, our goal is to develop bacteriophage-based treatments for multidrug-resistant bacteria, microbiome-based treatments using microbiota banking, and treatments related to autoimmune diseases and other untreatable diseases in the future. MicrobiotiX is a biotech company specializing in microbiome research established by professors from Yonsei Medical Center. With our microbiota collection and bacteriophage library we develop various treatments for multidrug-resistant bacteria and incurable diseases through exploring the interconnected relationship between the phages present in your intestines and the microbiome. We have built the world’s leading bacteriophage library over 15 years along with state-of-the-art research techniques in the field of bacteriophage and microbiome. In addition, we have built a GMP facility for a global scale up.
AT A GLANCE
Phage library of Gram-negative MDR pathogens | Possession of Asia’s 2nd oldest microbiota bank | Received approval for free pre-clinical serivce by the US institution | Pre-Series B investment round (DSC, Schmidt, SUP, Shinhan Capital) |
A venture established by specialists from Yonsei Medical Center | Got selected to be part of Shinhan2Bridge program | Joint research with CJ Bioscience | Establishment of a cGMP-class facility (CDMO service) |
MICROBIOTIX - CEO
Antimicrobial resistance is one of the
6 major challenges facing humanity
Antimicrobial agents are drugs that have saved countless lives since their discovery, but their development and pharmaceutical process is very slow and arduous. Microorganisms are gaining resistance to these antimicrobial agents. This undermines all of the hard work put into their development. This is due to the extreme diversity and genetic flexibility of these microorganisms. This problem is only expected to worsen in the future for 2 reasons: antimicrobial candidates are dwindling, and even with large investments, the new antimicrobial mechanism will be countered with just a few generations of mutations. Therefore, there is an urgent need to supplement or replace the existing antibacterial treatment framework. The countermeasures we must take are clear. Recently, the NIH in the United States proposed a shift to explore alternative therapies to overcome antimicrobial resistance, including bacteriophage therapy and synthetic microbiota. Yonsei University’s diagnostic laboratory, the academic foundation of MicrobiotiX, and the Institute of Bacterial Resistance have conducted a world-class antimicrobial resistance study. During this research, many world-first discoveries were made. The research team then explored innovative ways to overcome antimicrobial resistance and from this discussion MicrobiotiX was founded. The specific method that MicrobiotiX is currently pursuing is through bacteriophage therapy. Through bacteriophages, we want to reset the relationship between humans and antimicrobial resistant bacteria. Through, both Korean and American research teams, we are investigating phages to be used in preclinical and clinical trials. I’ll continue to work hard to push our research forward and I look forward to your support.
Dongeun Yong, CEO
MICROBIOTIX
KEY RESEARCHERS
Yong, Dongeun Professor Yonsei University’s School of Medicine Department of Laboratory Medicine Director of Infectious Diseases |
Cheon, Jaehee Professor Yonsei University’s School of Medicine Department of Gastroenterology Professor |
Park, Mooseok Professor Yonsei University’s School of Medicine Department of Pulmonology Professor |
Lee, Sangkil Professor Yonsei University’s School of Medicine Department of Gastroenterology Chief of Gastric Cancer Center |
Choi, Junyong Professor Yonsei University’s School of Medicine Department of Infectious Diseases Professor |
MICROBIOTIX
A BRIEF HISTORY
2022 | Received approval from US institution for free pre-clinical services Pre-series B with DSC Investment VC and Schmidt Bridge investment partners |
2021 | Pneumonia (Sepsis) treatment against pseudomonas aeruginosa infection. MP001 (first pipeline) got accepted to pre-clinical project (3.5 Billion) |
2020 | Transfer of 300 types of bacteriophages from Yonsei Medical Center |
2019 | IRB approval for bacteriophage therapy in clinical trials |
2018 | Ten bacteriophage-related patents transferred from Yonsei Medical Center |
2017 | Establishment of microbiota bank and FMT delivery for clinical use in hospitals |
2016 | MicrobiotiX founded |
PARTNERS
A Network
of Hospitals Nationwide
Seoul Yonsei Medical Center, Severance Hospital Yonsei Medical Center, Severance Hospital (Gangnam) Ewha Women’s University, Mokdong Hospital Hanyang University Hospital Samsung Medical Center Inje University, Sanggyebaek Hospital Nowoneulji University Hospital |
Gangwon province Hallim University, Chungcheon Sacred Heart Hospital |
Gwangju Metropolitan Area Jeollam University Hospital Joseon University Hospital |
Gyeonggi Province Catholic University , St. Mary’s Hospital (Bucheon) Catholic University, St. Vincent’s Hospital Cha University Medical Center, Bundangcha Hospital |
Daejeon Metropolitan Area Daejeon Eulji University Hospital |
Daegu Metropolitan Area Daegu Fatima Hospital |
Busan Metropolitan Area Goshin University, Gospel Hospital |
Incheon Metropolitan Area Gacheon University, Gil Hospital Catholic University, St. Mary’s Hospital (Incheon) |
Jeollabuk Province Jeonbuk University Hospital Wongwang University Hospital Jeonju Daejin Hospital |
Ulsan Metropolitan Area Ulsan University Hospital Donggang Hospital |
Jeju Province Jeju University Hospital |
MICROBIOTIX CO., LTD
IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)
TEL : 02. 6379. 2649
E-mail : mx@microbiotix.net
Copyright © MICROBIOTIX. All rights reserved.
INQUIRIES |
MICROBIOTIX CO., LTD
IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)
TEL : 02. 6379. 2649 l E-mail : mx@microbiotix.net
Copyright © MICROBIOTIX. All rights reserved.